To further support this point, two native samples of patients diagnosed with KIT D816V or FLT3 ITD positive AML were treated with crenolanib in dose-dilution assays for 48 hours and reduction of the viable (CD45 low positive) cell cohort was determined flow cytometrically. This evidence concerns the gene KIT and acute myeloid leukemia.